precison oncology

China’s Burning Rock Biotech completes Series C financing of RMB 850 million
By Dean Koh | 05:30 am | February 14, 2019
Burning Rock Biotech, which was founded in 2014 and focuses on NGS (Next-Generation Sequencing) diagnostics solutions for precision medicine in oncology, today announced the closing of the Series C financing totaling RMB 850 million.